Author pages are created from data sourced from our academic publisher partnerships and public sources.
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
OBJECTIVE The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of… Expand
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or… Expand
Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.
Surgical and pathologic findings at laparotomy for radical hysterectomy in 990 patients with clinical stage IB carcinoma of the cervix were analyzed to determine the frequency of metastases to the… Expand
Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium.
- C. Ehrlich, P. Young, F. Stehman, G. Sutton, W. M. Alford
- American journal of obstetrics and gynecology
- 1 April 1988
Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in… Expand
Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma
Between 30% and 50% of women who have high‐grade uterine leiomyosarcoma (uLMS) limited to the uterus at diagnosis remain progression‐free at 2 years. Adjuvant pelvic radiation does not improve… Expand
Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
OBJECTIVE The aim of this study was to determine the activity of paclitaxel in chemotherapy-naive patients with advanced or recurrent uterine leiomyosarcoma. METHODS Patients received 175 mg/m(2)… Expand
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group…
A phase II trial of ifosfamide and mesna in women with mixed mesodermal tumors of the ovary who had previously received platinum-containing chemotherapy was conducted by the Gynecologic Oncology… Expand
The risk of nodal metastasis in early adenocarcinoma of the uterine cervix*
- J. Bálega, H. Michael, +4 authors K. Look
- International journal of gynecological cancer…
- 1 January 2004
A functional and widely accepted definition of microinvasive cervical adenocarcinoma remains elusive. The purpose of this study was to determine at which depth of invasion the likelihood of lymph… Expand
Targeted Diagnostic Agent for Ovarian Cancer: Initial Clinical Results
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
- G. Sutton, F. Stehman, L. Einhorn, L. Roth, J. Blessing, C. Ehrlich
- Journal of clinical oncology : official journal…
- 1 February 1989
Fifty-six patients were randomly assigned to receive either one-day cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy (PAC-I) or five-day PAC (PAC-V) for advanced epithelial ovarian… Expand